Frontlight ResearchEarly access
TerminatedPhase 1
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Chicago, Memphis, and New York, United StatesSee the 3 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 4 people enrolled
- Started
- 25 Aug 2020
- Ended
- 6 Jan 2025
- Type of study
- Interventional
- Treatments tested
- OTQ923
- Record updated
- 8 January 2026
- Why it stopped
- The decision of early termination was made due to business reasons and was not a consequence of any safety concern.
Who can take part
- Age
- 2 years to 40 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female subjects age 2-40 years inclusive
- Confirmed diagnosis of sickle cell disease with globin typing (e.g. HbSS, HbSC, HbS/β0-thalassemia or others)
- Performance status >70% (Karnofsky for subjects >16 years of age and Lansky for subjects <16 years of age)
- At least one of the following indicators of disease severity as defined in the protocol - Vaso-occlusive pain crisis, Acute chest syndrome, Recurrent priapism, prior stroke, receive chronic transfusions, Red cell alloimmunization
- Subjects, who have failed, not tolerated or refused hydroxyurea therapy
Who cannot take part
- Prior HSCT or gene therapy
- Clinically significant active infection
- Seropositive for HIV or HTLV
- Active known malignancy, myelodysplasia, abnormal cytogenetics or immunodeficiency
- Known hepatic cirrhosis, bridging hepatic fibrosis or active hepatitis
- Severe or progressive arteriopathy or cerebrovascular disease, including Moyamoya; Other protocol defined inclusion/exclusion criteria may apply
- Available matched related donor for HSCT
- Protocol defined iron overload
- Cerebrovascular procedure within one year, including pial synangiosis for Moyamoya
Where in United States
- University of ChicagoChicago, United States
- St. Jude Children's Research HospitalMemphis, United States
- Memorial Sloan Kettering Cancer CtrNew York, United States
About the trial
What the trial wants to find out
This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.
The group in the trial
- OTQ923Treatment being tested
Single intravenous infusion of OTQ923 Part A - Adults treated with OTQ923; Part B - Children age 2-17 treated with OTQ923 based on review of data from Part A by Health agency after a formal interim analysis.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease
- Publications
- Future directions in transplantation for aplastic anemia.Hematology. American Society of Hematology. Education Program, 2025
- Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance.Transplantation and cellular therapy, 2024
- CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.The New England journal of medicine, 2023
- Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers.Pediatric blood & cancer, 2023
- Attitudes toward COVID-19 vaccine among pediatric patients with sickle cell disease and their caregivers.Pediatric blood & cancer, 2023
- Editing human hematopoietic stem cells: advances and challenges.Cytotherapy, 2023
- Record updated
- 8 January 2026